Author:
Ayres Rossini Guilherme,Pires Iyusuka Adelaide Margarida Lucatelli,Augusto Maria Durvanei
Abstract
The amount of patients which develop chronic irreversible illness rises as the life expectancy grows among countries. When cancer patients step into final stages of their illness the complexity of questions and situations is evident. Frequently, terminally ill cancer patients choose to use unprescribed therapies at their own risk to alleviate suffering. When a generalist doctor comes across these situations, bioethical questions tend to raise among physician’s minds when assisting the patient and family. In this paper we argue about phosphoethanolamine supplement scenario: the different points of view of regulatory agencies; bioethical considerations; theoretical aspects of the molecule as phospholipid precursor; the biological importance the relation to others systems in different levels; pre-clinical and clinical safety data.